X
X

Tom O'Brien

CEO

Prior to founding Eclipse in 1993, Tom held several leadership positions throughout his career in the medical device industry. Having mastered both disposable and capital equipment sales for companies like C.R. Bard, Tom’s track record of success quickly established Eclipse as the go-to company to launch new technology in the surgical laser industry.

Over time Tom transitioned Eclipse from a leader in the OR surgical laser market to a key player in the aesthetic laser industry. Starting in 2011 Eclipse began a new mission of increasing adoption of Platelet-rich Plasma on a national level.

His vision and leadership has helped Eclipse become one of the most successful medical device companies in its space. Tom’s new mission is to bring game-changing Eclipse technologies in Platelet-Rich Plasma, Microneedling and Shockwave Therapy to the entire globe.

X

Eclipse MedCorp Introduces Folliceuticals MD – A New Hair Health System

DALLAS, February 27, 2019 /PRNewswire/ — Eclipse, a leading medical manufacturing company, announced today the introduction of the Folliceuticals MD, a home-use system comprising an oral nutraceutical and topical foam for hair. Available only through physicians, Folliceuticals MD targets hair health from the inside out, while complementing in-office hair procedures.

“We see hair procedures as the biggest growth market in the dermatology and aesthetics space,” stated Tom O’Brien, CEO of Eclipse. “Combination therapy is well established as the ideal approach for hair loss patients. Folliceuticals MD will help physicians maximize successful outcomes and get patients invested in the process.”

Folliceuticals MD is the evolution of home hair therapy as it addresses multiple factors related to hair loss while encouraging overall patient health. Co-developed by our scientific team, including a board-certified dermatologist and hair loss expert, the proprietary formula for Folliceuticals MD uniquely targets the microbiome while also serving as a daily vitamin.

Dr. Sanjay Batra, President of Regenerative Medicine at Eclipse led the team that developed Folliceuticals MD, and added, “We are very proud of the science behind our proprietary formulations, and we plan to continue clinical evaluation and studies with our network of research physicians.”

Androgenetic alopecia is the most common form of hair loss in men and women. The etiology of this form of hair loss is believed to be multi-factorial. Folliceuticals MD was specifically designed with unique formulations for men and women with androgenetic alopecia. Using a topical and oral formulation, this system represents a best-in-class combination approach to treating hair loss without drugs.

Eclipse will be launching Folliceuticals MD at the 2019 American Academy of Dermatology Annual Meeting in Washington DC, February 28-March 3. Visit Eclipse booth #925 on Sunday at noon to hear Dr. Jeffrey Rapaport’s presentation on incorporating Folliceuticals MD into your dermatology practice.

To request more information about Folliceuticals MD call Eclipse at 800-759-6876 or email info@eclipsemed.com to schedule a meeting with your representative.

For USA & Canada visitors: EclipseMedGlobal.com is an international website that has not been evaluated by the United States Food and Drug Administration. Statements and/or claims on this site are not intended to prevent, diagnose, treat or cure any ailments or diseases. Information and product/packaging on this site is for informational purposes only and is not intended as a substitution for advice from a physician or health-care professional. Information shown on this site may describe clearances in countries other than the USA and Canada, hence it may include indications and information that are outside the scope of FDA-cleared labeling.

Do you understand and want to proceed?

 
Yes, please proceed

 

Visit the Eclipse USA Site